2WONG-BERINGER A, KRIENGKAUYKIAT J. Systemic antifungal theray: new options, new challenges [ J ]. Phannacotherpay,2003, 23(11) :1441-1462.
3CHANDRASEKAR PH, MANAVATHU E. Voficonazole: a second-generation triazole [J]. Drugs Today (Barc) , 2001, 37(2) :135-148.
4PFALLER MA, ZHANG J, MESSER SA, et al. In vitro activities of voriconazole, flubonazol, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa[J]. Antimicrob Agents Chemother, 1999, 43( 1 ) :169-171.
5SUTTON DA,SANCHE SE, REVANKAR SG, et ad. In vitro amplhotericin B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole [ J ]. J Clin Microbiol, 1999, 37(7) : 2343-2345.
6PURKINS L, WOOD N, KLEINERMANS D, et ad. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole [ J ]. Br J Clin Pharmacol, 2003, 56 Suppl 1 : 17-23.
7PURKINS L, WOOD N, GREENHALGH K, et al. The phannacokinetics and safety of intravenous voriconazol- a novel widespectrum antiftmgal agent [ J ]. Br J Clin Pharmacol, 2003, 56 Suppl 1:2-9.
8GUPTA AK, TOMAS E. New antifungal agents [ J ]. Dermatol Clin, 2003, 21 (3):565-576.
9OSTROSKY-ZEICHNER L, OUDE LASHOF AM, KUI.LBERG BJ, et o2. Voriconazole salvage treatment of invasive candidiasis[ J ]. Eur J Clin Microbiol Infect Dis, 2003, 22 ( 11 ) :651-655.
10RUBIO CALVO MC, GIL J, RAMIREZ de OCARIZ I, et al. In vitro activity of tluconazole, voriconazole and posaconazole against Candida spp [J]. Rev Esp Quimioter, 2003, 16(2) :227-232.
